立体定向体部放疗根治性治疗超大(≥100 cc)前列腺癌
回顾性分析71例前列腺体积≥100 cc且接受根治性机器人立体定向体部放疗的局限期前列腺癌患者,中位毒性随访4.0年,2年1级及以上泌尿生殖毒性43.5%、1级及以上胃肠道毒性15.9%、2级及以上泌尿生殖毒性30.4%,3级泌尿生殖毒性仅2.8%。治疗前使用泌尿生殖药物与2级及以上泌尿生殖毒性升高显著相关(OR 3.19,P=0.024),前列腺体积连续变量对毒性、生活质量及肿瘤学结局无影响。
要点
- 71例前列腺体积≥100 cc患者接受5次3500至3625 cGy的立体定向体部放疗,中位毒性随访4.0年。
- 2年1级及以上泌尿生殖毒性43.5%,2级及以上泌尿生殖毒性30.4%,3级泌尿生殖毒性2.8%,无3级胃肠道毒性。
- 治疗前使用泌尿生殖药物与2级及以上泌尿生殖毒性升高显著相关(OR 3.19,P=0.024)。
核心结论
- 早期随访下,超大前列腺(≥100 cc)接受立体定向体部放疗后不预示高等级毒性风险增加,但可能增加低等级泌尿生殖毒性风险。
研究设计与样本
- 回顾性分析一家大型机构数据库,纳入组织学确诊的局限期前列腺癌且前列腺体积≥100 cc、接受根治性机器人立体定向体部放疗的患者71例。
- 前列腺体积由治疗计划磁共振成像确定,毒性采用不良事件通用术语标准5.0版评估,许多患者完成扩展前列腺癌综合指数生活质量问卷,最短随访2年。
主要发现
- 多数患者为分级分组1或2级(分别为41%和37%),全部患者接受5次3500至3625 cGy的总剂量。
- 少数患者(27%)接受雄激素剥夺治疗,其中仅10%的病例用于缩小前列腺体积。
- 近半数患者(45%)在放疗前因排尿功能障碍使用泌尿生殖药物。
- 2年1级及以上泌尿生殖毒性、1级及以上胃肠道毒性、2级及以上泌尿生殖毒性发生率分别为43.5%、15.9%、30.4%。
- 3级泌尿生殖毒性总计非常有限(2.8%),无3级胃肠道毒性;逻辑回归分析显示治疗前使用泌尿生殖药物与2级及以上泌尿生殖毒性发生率升高显著相关(比值比3.19,P=0.024),前列腺体积(作为连续变量分析)对毒性、生活质量或肿瘤学结局无影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Historically, toxicity concerns have existed in patients with large prostate glands treated with radiation therapy, particularly brachytherapy. There are questions whether this risk extends to stereotactic body radiation therapy (SBRT). In this retrospective review, we examine clinical outcomes of patients with prostate glands ≥100 cc treated curatively with SBRT. METHODS AND MATERIALS: We retrospectively analyzed a large institutional database to identify patients with histologically confirmed localized prostate cancer in glands ≥100 cc, who were treated with definitive-robotic SBRT. Prostate volume (PV) was determined by treatment planning magnetic resonance imaging. Toxicity was measured using Common Terminology Criteria for Adverse Events, version 5.0. Many patients received the Expanded Prostate Cancer Index Composite Quality of Life questionnaires. Minimum follow-up (FU) was 2 years. RESULTS: Seventy-one patients were identified with PV ≥100 cc. Most had grade group (GG) 1 or 2 (41% and 37%, respectively) disease. All patients received a total dose of 3500 to 3625 cGy in 5 fractions. A minority (27%) received androgen deprivation therapy (ADT), which was used for gland size downsizing in only 10% of cases. Nearly half (45%) were taking GU medications for urinary dysfunction before RT. Median toxicity FU was 4.0 years. Two-year rates of grade 1+ genitourinary (GU), grade 1+ gastrointestinal (GI), and grade 2+ GU toxicity were 43.5%, 15.9%, and 30.4%, respectively. Total grade 3 GU toxicities were very limited (2.8%). There were no grade 3 GI toxicities. On logistic regression analysis, pretreatment use of GU medications was significantly associated with increased rate of grade 2+ GU toxicity (odds ratio, 3.19; P = .024). Furthermore, PV (analyzed as a continuous variable) did not have an effect on toxicity, quality of life, or oncologic outcomes. CONCLUSIONS: With early FU, ultra large prostate glands do not portend increased risk of high-grade toxicity after SBRT but likely carry an elevated risk of low-grade GU toxicity.
引用
- Hurwitz JC, Haas J, Mendez C, et al. Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) Glands. Pract Radiat Oncol. 2023. PMID: 37984713. doi:10.1016/j.prro.2023.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。